These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 31280022)

  • 1. Comparison of pharmacodynamics and pharmacokinetics of insulin degludec and insulin glargine 300 U/mL in healthy cats.
    Gilor C; Culp W; Ghandi S; do Carmo Emidio E Silva JA; Ladhar A; Hulsebosch SE
    Domest Anim Endocrinol; 2019 Oct; 69():19-29. PubMed ID: 31280022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of pharmacodynamics between insulin glargine 100 U/mL and insulin glargine 300 U/mL in healthy cats.
    Saini NK; Wasik B; Pires J; Leale DM; Quach N; Culp WTN; Samms RJ; Johnson AE; Owens JG; Gilor C
    Domest Anim Endocrinol; 2021 Apr; 75():106595. PubMed ID: 33307335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine.
    Heise T; Hövelmann U; Nosek L; Hermanski L; Bøttcher SG; Haahr H
    Expert Opin Drug Metab Toxicol; 2015; 11(8):1193-201. PubMed ID: 26086190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin degludec: Lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes.
    Heise T; Nørskov M; Nosek L; Kaplan K; Famulla S; Haahr HL
    Diabetes Obes Metab; 2017 Jul; 19(7):1032-1039. PubMed ID: 28295934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Day-to-Day and Within-Day Variability in Glucose-Lowering Effect Between Insulin Degludec and Insulin Glargine (100 U/mL and 300 U/mL): A Comparison Across Studies.
    Heise T; Kaplan K; Haahr HL
    J Diabetes Sci Technol; 2018 Mar; 12(2):356-363. PubMed ID: 28946756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin Degludec Versus Insulin Glargine on Glycemic Variability in Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Yang Y; Long C; Li T; Chen Q
    Front Endocrinol (Lausanne); 2022; 13():890090. PubMed ID: 35721710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of glycemic variability in Japanese patients with type 1 diabetes receiving insulin degludec versus insulin glargine using continuous glucose monitoring: A randomized, cross-over, pilot study.
    Onda Y; Nishimura R; Ando K; Takahashi H; Tsujino D; Utsunomiya K
    Diabetes Res Clin Pract; 2016 Oct; 120():149-55. PubMed ID: 27562434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin doses requirements in patients with type 1 diabetes using glargine U300 or degludec in routine clinical practice.
    Carral San Laureano F; Tomé Fernández-Ladreda M; Jiménez Millán AI; García Calzado C; Ayala Ortega MDC
    J Investig Med; 2021 Jun; 69(5):983-988. PubMed ID: 33771843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamics and pharmacokinetics of insulin detemir and insulin glargine 300 U/mL in healthy dogs.
    Fink H; Herbert C; Gilor C
    Domest Anim Endocrinol; 2018 Jul; 64():17-30. PubMed ID: 29709796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamics of insulin detemir and insulin glargine assessed by an isoglycemic clamp method in healthy cats.
    Gilor C; Ridge TK; Attermeier KJ; Graves TK
    J Vet Intern Med; 2010; 24(4):870-4. PubMed ID: 20561185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of insulin degludec U100 and insulin glargine U100 in combination with meal-time bolus insulin in hospitalized patients with type 2 diabetes: an open-label, randomized controlled study.
    Suzuki J; Yamakawa T; Oba M; Nagakura J; Shigematsu E; Tamura H; Takahashi K; Okamoto Y; Sakamoto R; Shinoda M; Takano T; Kadonosono K; Terauchi Y
    Endocr J; 2019 Nov; 66(11):971-982. PubMed ID: 31270291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes.
    Heise T; Nosek L; Bøttcher SG; Hastrup H; Haahr H
    Diabetes Obes Metab; 2012 Oct; 14(10):944-50. PubMed ID: 22726241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of insulin glargine 300 units/mL vs insulin degludec in patients with type 1 and type 2 diabetes: a systematic review and meta-analysis.
    Alhmoud EN; Saad MO; Omar NE
    Front Endocrinol (Lausanne); 2023; 14():1285147. PubMed ID: 38313835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic and pharmacodynamic responses of insulin degludec in African American, white, and Hispanic/Latino patients with type 2 diabetes mellitus.
    Hompesch M; Morrow L; Watkins E; Roepstorff C; Thomsen HF; Haahr H
    Clin Ther; 2014 Apr; 36(4):507-15. PubMed ID: 24508419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Insulin Degludec and Insulin Glargine U300 on Day-to-Day Fasting Plasma Glucose Variability in Individuals with Type 1 Diabetes: A Multicenter, Randomized, Crossover Study (Kobe Best Basal Insulin Study 2).
    Miura H; Sakaguchi K; Okada Y; Otowa-Suematsu N; Yamada T; So A; Komada H; Hirota Y; Kishi M; Takeda A; Tominaga Y; Nakamura T; Kuroki Y; Matsuda T; Iida K; Kajikawa M; Ohara T; Yokota K; Hara K; Tateya S; Tamori Y; Ogawa W
    Diabetes Ther; 2018 Dec; 9(6):2399-2406. PubMed ID: 30341665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The differences between insulin glargine U300 and insulin degludec U100 in impact on the glycaemic variability, arterial stiffness and the lipid profiles in insulin naïve patients suffering from type two diabetes mellitus - outcomes from cross-over open-label randomized trial.
    Cindro PV; Krnić M; Modun D; Smajić B; Vuković J
    BMC Endocr Disord; 2021 Apr; 21(1):86. PubMed ID: 33926446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical relevance of pharmacokinetic and pharmacodynamic profiles of insulin degludec (100, 200 U/mL) and insulin glargine (100, 300 U/mL) - a review of evidence and clinical interpretation.
    Owens DR; S Bailey T; Fanelli CG; Yale JF; Bolli GB
    Diabetes Metab; 2019 Sep; 45(4):330-340. PubMed ID: 30496834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes.
    Heise T; Hermanski L; Nosek L; Feldman A; Rasmussen S; Haahr H
    Diabetes Obes Metab; 2012 Sep; 14(9):859-64. PubMed ID: 22594461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of insulin degludec and insulin glargine U300 on glycaemic stability in individuals with type 1 diabetes: A multicentre, randomized controlled crossover study.
    Miura H; Sakaguchi K; Otowa-Suematsu N; Yamada T; So A; Komada H; Okada Y; Hirota Y; Tamori Y; Ogawa W
    Diabetes Obes Metab; 2020 Dec; 22(12):2356-2363. PubMed ID: 32744395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Insulin Glargine 300 U/mL and Insulin Degludec 100 U/mL Around Spontaneous Exercise Sessions in Adults with Type 1 Diabetes: A Randomized Cross-Over Trial (ULTRAFLEXI-1 Study).
    Moser O; Müller A; Aberer F; Aziz F; Kojzar H; Sourij C; Obermayer A; Abbas F; Birnbaumer P; Lenz J; Mursic I; Sternad C; Hönger L; Ziko H; Pferschy PN; Tripolt N; Sourij H
    Diabetes Technol Ther; 2023 Mar; 25(3):161-168. PubMed ID: 36516429
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.